Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18087548 | 1.00 | TSHR (0.47) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL2251871 | 1.00 | TSHR (0.47) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL30060557 | 0.85 | TSHR (0.38) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL6153825 | 0.84 | LMNA (0.45) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL127431 | 0.81 | MMP1 (0.58) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL2275330 | 0.81 | LMNA (0.46) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL27940205 | 0.80 | MMP1 (0.38) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL27343936 | 0.80 | LMNA (0.42) | TSHRLMNAMMP1MMP2MMP3 | |
| SCHEMBL27422771 | 0.80 | MMP1 (0.38) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL27650654 | 0.80 | MMP1 (0.38) | TSHRMMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-110099912-B | Antiviral tenofovir aliphatic ester prodrug | 默沙东公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-110099912-A | Antiviral tenofovir aliphatic ester prodrug | 默沙东公司 | 2019-08-06 | — | — | CN | disclosed |
| US-20180179208-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | TSHR 3434/4885LMNA 1938/4885MMP1 4345/4885 |
| US-20180179208-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | TYMP, PNP, GART | TSHR 4243/4885LMNA 2318/4885MMP1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.